1 1063 Lower Main St, Ste C212 JEFFREY H. CHESTER, DO Phone Board Certified by American Board of Physical Medicine & Rehabilitation Board Certified by American Society of Addiction Medicine Fax Physiatry/Pain Management/Electrodiagnostic Medicine/EMG/Osteopathic Manual Medicine/Opioid Addiction Treatment Patient Information and Consent to Treatment with Buprenorphine Patient s Name (printed): Buprenorphine with or without naloxone is an FDA approved medication for treatment of people with heroin or other opioid addiction. Buprenorphine can be used for detoxification or for maintenance therapy. Maintenance therapy can continue as long as medically necessary. There are other treatments for opiate addiction, including methadone, naltrexone, and some treatments without medications that include counseling, groups and meetings. Buprenorphine sometimes used off label for pain. If you are dependent on opiates - any opiates - you should be in as much withdrawal as possible when you take the first dose of buprenorphine. It you are not in withdrawal, buprenorphine can cause severe opiate withdrawal. We recommend that you arrange not to drive after your first dose, because some patients get drowsy until the correct dose is determined for them. Some patients find that it takes several days to get used to the transition from the opiate they had been using to buprenorphine. During that time, any use of other opiates may cause worsened symptoms. Attempts to override the buprenorphine by taking more opiates could result in an opiate overdose. You should not take any other medication without discussing it with the physician first. Combining buprenorphine with alcohol or other sedating medications is dangerous. The combination of buprenorphine with benzodiazepines (such as Valium, Librium, Ativan, Xanax, Klonopin, etc.) has resulted in deaths. Although sublingual (under the tongue) buprenorphine is very unlikely to be liver-damaging, your doctor may monitor your liver tests while you are taking buprenorphine. (This is a blood test.) The form of buprenorphine you may be taking could be a combination of buprenorphine with a short-acting opiate blocker (naloxone). It will maintain physical dependence, and if you discontinue it suddenly, you will likely experience withdrawal. If the Suboxone tablet were dissolved and injected by someone taking heroin or another strong opioid, it could cause severe opiate withdrawal. Buprenorphine tablets must be held under the tongue until they dissolve completely. It is important not to talk or swallow until the tablet dissolves. This takes up to ten minutes. Buprenorphine is then absorbed over the next 30 to 120 minutes from the tissue under the tongue. Buprenorphine will not be absorbed from the stomach if it is swallowed. If you swallow the tablet, you will not have the important benefits of the medication, and it may not relieve your withdrawal. Most patients end up at a daily dose of 16 mg to 24mg of buprenorphine. (This is roughly equivalent to 60mg of methadone maintenance). Beyond that dose, the effects of buprenorphine plateau, so there may not be any more benefit to increase in dose. It may take several weeks to determine just the right dose for you. The first dose is usually 2mg to 4mg. If you are transferring to buprenorphine from methadone maintenance, your dose should ideally be tapered until you have been below 30mg, preferably for at least a week. There must be at least 24 hours (preferably longer) between the time you take your last methadone dose and the time you are given your first dose of buprenorphine. You should not begin buprenorphine until you are in withdrawal. Buprenorphine treatment/substance abuse treatment fees have been provided to me. Dr. Chester s office fees are kept current. I have also been provided with a copy of Hawaii Physician s Licensed to Prescribe Buprenorphine and Other Substance Abuse Treatment Centers on Maui.
2 Alternatives to buprenorphine: Some hospitals that have specialized drug abuse treatment units can provide detoxification and intensive counseling for drug abuse. Some outpatient drug abuse treatment services also provide individual and group therapy, which may emphasize treatment that does not include maintenance on buprenorphine or other opiate like medications. Other forms of opioid maintenance therapy include methadone maintenance. Some opioid treatment programs use naltrexone, a medication that blocks the effects of opioids, but has no opioid effects of its own. I have read the two pages and understand these details about buprenorphine treatment. I wish to be treated with buprenorphine. Patient Signature Patient s Name printed: Witness Signature
3 1063 Lower Main St, Ste C212 JEFFREY H. CHESTER, DO Phone Board Certified by American Board of Physical Medicine & Rehabilitation Board Certified by American Society of Addiction Medicine Fax Physiatry/Pain Management/Electrodiagnostic Medicine/EMG/Osteopathic Manual Medicine/Opioid Addiction Treatment Agreement for Treatment with Buprenorphine (Subutex /Suboxone ) Patient s Name (printed): By signing below, I agree to the following: 1. Buprenorphine treatment for opiate dependence is most effective when combined with drug abuse counseling, 12-step recovery work, or a recovery support group. During my treatment with buprenorphine, I agree to seek additional counseling and to work on a program of recovery. 2. I agree that my physician can coordinate my medication switch from methadone to buprenorphine with my provider of methadone. This may involve exchange of medical records and discussions with the clinic physician or staff. After switching to buprenorphine, I will not take methadone, unless otherwise directed by my physician. 3. I understand that on the day I start buprenorphine, if I am not having observable signs of opiate withdrawal, induction onto buprenorphine may be delayed. 4. My first dose of buprenorphine will be 2mg to 4 mg. After a couple of hours, I may be administered additional doses of buprenorphine. 5. Take home doses and frequency of visits will be determined by how well I am doing. 6. I agree to take buprenorphine as prescribed at the dosage determined by my physicians, and not to allow anyone else to take medication prescribed for me. 7. I agree not to take other medications with buprenorphine without prior permission from my doctor. I understand that overdose deaths have occurred when patients have taken other medications (particularly medications like Librium, Valium or other benzodiazepines) with buprenorphine. 8. I understand that buprenorphine itself is an opiate drug and can produce physical dependence that is similar to heroin. 9. The goal of treatment of opiate dependency is to learn to live without abuse of drugs. Buprenorphine treatment should continue as long as necessary to prevent relapse to opiate abuse/dependence. 10. Periodic testing for drugs of abuse is to detect early relapse and to document my progress in treatment. 11. Lost prescriptions or buprenorphine tablets are a serious issue and may result in discontinuation of buprenorphine therapy from this office, or need more frequent office visits. 12. I agree to tell my physician if I become pregnant or even think I may be pregnant. I have read and understand these details about buprenorphine treatment. I wish to be treated with buprenorphine. Patient Signature Signature of provider obtaining consent Date Date
4 1063 Lower Main St, Ste C212 JEFFREY H. CHESTER, DO Phone Board Certified by American Board of Physical Medicine & Rehabilitation Board Certified by American Society of Addiction Medicine Fax Physiatry/Pain Management/Electrodiagnostic Medicine/EMG/Osteopathic Manual Medicine/Opioid Addiction Treatment Agreement for Treatment with Buprenorphine (Subutex or Suboxone ) Yes No 1. I agree to keep all my appointments. I understand that if I do not keep my scheduled appointments, Dr. Chester will possibly discharge me from treatment and refer me to other substance abuse treatment facilities or will likely require more frequent office visits each month. Yes No 2. I agree to report my history and my symptoms honestly to Dr. Chester. I also agree to inform Dr. Chester of all other physicians and dentists whom I am seeing; of all prescription and nonprescription drugs I am taking; of any alcohol or street drugs I have recently been using; and whether I have become pregnant or have developed hepatitis. Yes No 3. I agree to cooperate with urine drug testing whenever requested by Dr. Chester, to confirm if I have been using any alcohol, prescription drugs, or street drugs. Yes No 4. I have been informed that buprenorphine, as found in Suboxone and Subutex, is a narcotic analgesic, and thus it can produce a 'high'; I know that taking buprenorphine regularly can lead to physical dependence and addiction, and that if I were to abruptly stop taking buprenorphine after a period of regular use, I could experience symptoms of opiate withdrawal. Yes No 5. I have been informed that buprenorphine is to be placed under the tongue for it to dissolve and be absorbed, and that it should never be injected or taken I.V. I have been informed that injecting buprenorphine after taking buprenorphine or any other opiate regularly could lead to sudden and severe opiate withdrawal. Yes No 6. I have been informed that buprenorphine is a powerful drug and is to be respected, and that supplies of it must be protected from theft or unauthorized use, since persons who want to get high by using it or who want to sell it for profit, may be motivated to steal my take-home prescription supplies of buprenorphine. Yes No 7. I have a means to store take-home prescription supplies of buprenorphine safely, where it cannot be taken accidentally by children or pets, or stolen by unauthorized users. I agree that if my buprenorphine pills are swallowed by anyone besides me, I will call 911 or Poison Control at immediately. Yes No 8. I agree that if Dr. Chester recommends that my home supplies of buprenorphine should be kept in the care of a responsible member of my family or another third party, I will abide by such recommendations. Yes No 9. I will be careful with my take-home prescription supplies of buprenorphine, and agree that I have been informed that if I report that my supplies have been lost or stolen, that my doctors will not be requested or expected to provide me with make-up supplies. This means that if I run out of my medication supplies it could result in my experiencing symptoms of opiate withdrawal. Also, I agree that if there has been a theft of my medications, I will report this to the police and will bring a copy of the police report to my next appointment with Dr. Chester. Yes No 10. I agree to bring my bottle of buprenorphine in with me for every appointment with Dr. Chester, if requested, so that remaining supplies can be counted. Yes No 11. I agree to take my buprenorphine as prescribed, to not skip doses, and that I will not adjust the dose without talking with Dr. Chester about this so that changes in orders can be properly communicated by Dr. Chester to my pharmacy. Yes No 12. I agree that I will not drive a motor vehicle or use power tools or other dangerous machinery during my first days of taking buprenorphine, to make sure that I can tolerate taking it without becoming sleepy or clumsy as a side-effect of taking it.
5 Yes No 13. I agree that I will arrange transportation to and from Dr. Chester s office during my first days of taking buprenorphine so that I do not have to drive myself to and from the office. Yes No 14. I have been informed that it can be dangerous to mix buprenorphine with alcohol or another sedative drug such as Valium, Librivan, Ativan, Xanax, Klonopin or any other benzodiazepine drug--so dangerous that it could result in accidental overdose, over-sedation, coma, or death. I agree to use no alcoholic beverages and to take no sedative drugs at any time while being treated with buprenorphine. Yes No, I am NOT pregnant 15. I am not pregnant, and will not attempt to become pregnant. If a female, I will not have unprotected sex while I am taking buprenorphine, because of the unknown safety of buprenorphine during pregnancy. I have been informed by Dr. Chester that special considerations are necessary for buprenorphine treatment if I become pregnant. Yes No 16. I want to be in recovery from addiction to all drugs, and I have been informed that any active addiction to other drugs besides heroin and other opiates must be treated by counseling and other methods. I have been informed that buprenorphine is a treatment designed to treat opiate dependence, not addiction to other classes of drugs. Yes No 17. I agree that medication management of addiction with buprenorphine is only one part of the treatment of my addiction, and I agree to participate in a regular program of professional counseling while being treated with buprenorphine. Yes No 18. I agree that professional counseling for addiction has the best results when patients also are open to support from peers who are also pursuing recovery. Yes No 19. I agree to participate in a regular program of peer/self-help while being treated with buprenorphine. Yes No 20. I agree that the support of loved ones is an important part of recovery, and I agree to invite significant persons in my life to participate in my treatment with Dr. Chester. Yes No 21. I agree that a network of support, and communication among persons in that network, is an important part of my recovery. I will be asked for my authorization, if required (which it almost always is) to allow telephone, , or face-to-face contact, as appropriate, between Dr. Chester and outside parties, including physicians, therapists, probation and parole officers, and other parties, when Dr. Chester has decided that open communication about my case, on my behalf, is necessary. Yes No 22. I agree that I will be open and honest with my counselors and inform Dr. Chester about cravings, potential for relapse to the extent that I am aware of such, and specifically about any relapse which has occurred --before a drug test result shows it. Yes No 23. I have been given a copy of Dr. Chester s procedures and responsibilities to me as a recipient of addiction treatment services, including buprenorphine treatment. Yes No 24. I have been provided with a copy of Hawaii Physician s Licensed to Prescribe Buprenorphine and Other Substance Abuse Treatment Centers in Hawaii. Yes No 25. I understand that Dr. Chester s office hours are Monday through Friday, from 9:00am until 4:00pm. The office phone number is Patient Signature Patient s Name (printed): Witness Signature
6 Maui Physicians Certified for Buprenorphine Treatment Name Address Phone George Carlson, MD 645 Laniolu Place Kihei, HI Lower Main Street Suite C-212 (808) (808) Sadye Yvonne Conner, MD 3246 Luahine Place Haiku, HI (808) Paul Adam Kaiwi, Jr. Royal Randolph, Jr., MD 444 Hana Highway Suite 201 Kahului, HI One Main Plaza Building 2200 Main Street, Ste 517, P.O. Box 1441 (808) (808) Michael Lawrence Rimm, MD Zehra Siddiqui, MD 1043 Makawao Avenue Suite 201 Makawao, HI Maui Lani Parkway (808) (808) Maui Treatment Programs Offering Buprenorphine Treatment Name Address Phone CHAMP Clinic of Maui (Comprehensive health and Attitude Management Program) 270 Waiehu Beach Rd, #115 (808) Intake: (808) Source:
7 Other Substance Abuse Treatment Centers on Maui NAME ADDRESS PHONE 1 Malama Na Makua A Keiki DBA Malama Family Recovery Center Outpatient Substance abuse treatment, Halfway house Special Programs/Groups: Persons with co-occurring mental and substance abuse disorders, Pregnant/postpartum women, Women 388 Ano St, Kahului, HI Intake: Kaiser Permanente Behavioral Health Services Outpatient Substance abuse treatment Wells St, Ste Aloha House, Inc Therapeutic Living Program (TLP) / Adult Residential Treatment Ike Dr, Makawao, HI Intake: Aloha House, Inc Outpatient Services West Vineyard St, Suite 200, Crisis Hotline: Ohana Makamae, Inc Outpatient Substance abuse treatment, Halfway house Special Programs/Groups: Adolescents 39 Keanini St, Hana, HI Maui Community Mental Health Center 121 Mahalani St, Intake: Maui Memorial Medical Center Behavioral Health 221 Mahalani St, Intake: Hawaii State/Dept of Health CAMHD Maui FGC/Wailuku Office 270 Waiehu Beach Rd, Suite Intake: Maui Youth and Family Services Inc Adolescent Community Base Program 1931 Baldwin Ave, Makawao, HI Intake: Maui Youth and Family Services Inc Lahaina House IOP/OP 894 Kuhua St, Lahaina, HI Intake: Source:
OFFICE-BASED BUPRENORPHINE THERAPY FOR OPIOID DEPENDENCE: IMPORTANT INFORMATION FOR PRESCRIBERS BUPRENORPHINE-CONTAINING TRANSMUCOSAL PRODUCTS I. INTRODUCTION The purpose of this brochure is to provide
Opioid Treatment Agreement 1. I understand that my provider and I will work together to find the most appropriate treatment for my chronic pain. I understand the goals of treatment are not to eliminate
WISCONSIN Opioid Treatment Program PATIENT REFERENCE HANDBOOK Department of Health Services Division of Mental Health and Substance Abuse Services Bureau of Prevention, Treatment and Recovery P-23048 (08/2015)
Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction
Patient Demographics Referring Physician: City/State: Phone Number: Legal Name: Date of Birth: / / Age: M F Social Security Number: Martial Status: M S W D Physical Address: City: State: Zip: Mailing Address:
College of Physicians and Surgeons of Saskatchewan Saskatchewan METHADONE GUIDELINES AND STANDARDS for the Treatment of Opioid Addiction/Dependence March, 2015 cps.sk.ca ACKNOWLEDGEMENTS The information
Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office April 2013 The recommendations contained herein were adopted as policy by the House of Delegates of the Federation of State
Principles for the Provision of Opioid Dependence Treatment By Manitoba Pharmacists ACKNOWLEDGEMENTS The College of Pharmacists of Manitoba would like to thank the following organizations and individuals
Michigan Department of Community Health, Behavioral Health and Developmental Disabilities Administration BUREAU OF SUBSTANCE ABUSE AND ADDICTION SERVICES TREATMENT POLICY #05 SUBJECT: Criteria for Using
the facts about BUPRENORPHINE for Treatment of Opioid Addiction U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment
Methadone Maintenance Treatment Policies and Procedures For New Brunswick Addiction Services February 2009 TABLE OF CONTENTS PURPOSE:... 1 FUNCTION AND ACTIVITIES... 2 GOALS AND OBJECTIVES... 3 REFERRAL
Medication-Assisted Treatment for Opioid Addiction Facts for Families and Friends U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance
Substance Abuse Services for Youth in Florida: A Guide for Families March 2009 Florida Certification Board/Southern Coast ATTC Monograph Series #4 Substance Abuse Services for Youth in Florida: A Guide
Opioid Addiction Treatment in Wisconsin: An Assessment of Need and Options for Expanding Access Prepared for the Wisconsin Legislative Council By Karole Dachelet Drake Daily Ben Kopitzke Hannah Vogel Tyrel
Alberta Methadone Maintenance Treatment STANDARDS AND GUIDELINES FOR DEPENDENCE 2014 Table of Contents Introduction... 1 Standards and Guidelines - Overview... 3 Methadone Maintenance Treatment in Alberta...
Journal of Adolescent Health 40 (2007) 477 482 Clinical observation Buprenorphine Replacement Therapy for Adolescents with Opioid Dependence: Early Experience from a Children s Hospital-Based Outpatient
Sastry K. Topalli, MD Diplomate of the American Board of PM&R Board Certified in PM&R 676 Battlefield Blvd N, Suite B Chesapeake, VA 23320 Phone: 757-410-4219 Fax: 757-410-4237 www.atlanticpaininterventions.com
The ACT Opioid Maintenance Treatment Guidelines ACT Health Due for review September 2012 TABLE OF CONTENTS 1 PURPOSE OF THE GUIDELINES... 3 2 KEY ROLES... 3 3 RELATED POLICIES, GUIDELINES AND LEGISLATION...
22 Kislev, 5770 29 November, 2010 Document No. 38299410 The Health Ministry's of Substance Abuse's Policy Regarding: Treating Opiate Addicts with Medication for an Extended Period of Time (using agonist
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment www.samhsa.gov Acknowledgments This booklet was produced by Johnson,
Questions to Ask Treatment Programs Are you looking for a drug and alcohol treatment program for your teen or young adult? This list of questions can help guide your conversation with treatment program
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
New Mexico Treatment Guidelines For Medical Providers Who Treat Opioid Addiction Using Buprenorphine Miriam Komaromy, M.D. Robert Buser, M.D. Harris Silver, M.D. Leslie Hayes, M.D. Julie Bohan, M.D. Daniel
Medication treatments for opioid use disorders Summary for counties JUDITH MARTIN, Medical Director of Substance Use Services, San Francisco Department of Public Health Brief history of Methadone and Buprenorphine